Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study

Bristol Myers Squibb & Co BMY has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC).
The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary efficacy endpoints.
The safety profile of deucravacitinib was consistent with previously reported studies in psoriasis and psoriatic arthritis, and no new safety signals were observed.
The Company will complete a full review of the data from LATTICE-UC.
The potential of deucravacitinib in UC continues to be evaluated in IM011-127, a second Phase 2 trial that includes a higher dose.
Bristol Myers Squibb continues to expect over $4 billion non-risk adjusted revenue target for deucravacitinib in 2029.
Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor.
Price Action: BMY stock is up 0.14% at $59.27 during the market session on the last check Thursday.